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Background: There is little reliable information on the prevalence of fetal alcohol spectrum disorders (FASD) in
Australia and no coordinated national approach to facilitate case detection. The aim of this study was to identify
health professionals’ perceptions about screening for FASD in Australia.
Method: A modified Delphi process was used to assess perceptions of the need for, and the process of, screening for
FASD in Australia. We recruited a panel of 130 Australian health professionals with experience or expertise in FASD
screening or diagnosis. A systematic review of the literature was used to develop Likert statements on screening coverage,
components and assessment methods which were administered using an online survey over two survey rounds.
Results: Of the panel members surveyed, 95 (73%) responded to the questions on screening in the first survey round and,
of these, 81 (85%) responded to the second round. Following two rounds there was consensus agreement on the need for
targeted screening at birth (76%) and in childhood (84%). Participants did not reach consensus agreement on the need for
universal screening at birth (55%) or in childhood (40%). Support for targeted screening was linked to perceived constraints
on service provision and the need to examine the performance, costs and benefits of screening.
For targeted screening of high risk groups, we found highest agreement for siblings of known cases of FASD (96%) and
children of mothers attending alcohol treatment services (93%). Participants agreed that screening for FASD primarily
requires assessment of prenatal alcohol exposure at birth (86%) and in childhood (88%), and that a checklist is needed to
identify the components of screening and criteria for referral at birth (84%) and in childhood (90%).
Conclusions: There is an agreed need for targeted but not universal screening for FASD in Australia, and sufficient
consensus among health professionals to warrant development and evaluation of standardised methods for targeted
screening and referral in the Australian context. Participants emphasised the need for locally-appropriate, evidence-based
approaches to facilitate case detection, and the importance of ensuring that screening and referral programs are supported
by adequate diagnostic and management capacity.Background
Prenatal alcohol exposure causes a range of disorders of fetal
development [1-3]. The term fetal alcohol spectrum
disorders (FASD) is used to identify one group of conditions
that can result from prenatal exposure to alcohol [4].
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defects [5-8], although the spectrum of disorders most
commonly includes impairments of neurological func-
tion that are not accompanied by characteristic facial
anomalies or growth deficit [9,10]. There is some vari-
ation in the range of disorders recognised within the
spectrum and the use of specific diagnostic termin-
ology between different diagnostic guidelines. How-
ever, all guidelines include the well-established
diagnostic category of fetal alcohol syndrome (FAS)
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disorder (ARND) or its equivalent [6,8,11,13].
The diagnosis of FASD is often delayed or missed
[4,14-16], despite evidence linking diagnosis and inter-
vention to improved educational, social and health
outcomes [17,18]. Failure to identify children with FASD
has been attributed to the limited ability of health ser-
vice providers to access affected children and their
mothers, a lack of accurate routine screening for FASD
or of routine screening for maternal alcohol use during
pregnancy, limited clinical capacity to recognise and
diagnose these disorders, and the difficulty of identifying
all but the most severe cases at birth [19,20]. The identi-
fication of FASD in Australia is likely to be limited by poor
awareness of diagnostic features among paediatricians [21]
and other health professionals [22], and the absence of na-
tional guidelines for diagnosis. Concern about stigma as a
result of diagnosis [22] may also influence the willingness
to diagnose or to be diagnosed.
There is only limited information available on the
prevalence of FASD in Australia [15], with no routine
screening or surveillance established for the disorders.
The need to address significant gaps in the capacity to
identify and diagnose FASD in Australia is reflected in
recent health policy [23] and the launch of an Australian
federal government inquiry into the incidence and pre-
vention of FASD in 2011 [24]. Although not yet
implemented, the Western Australian FASD Model of
Care [23] recommends multi-stage population screening
to identify at risk newborns and children based on his-
tory of maternal alcohol consumption, abnormal growth
parameters and developmental delay. Targeted screening is
also recommended in a number of sub-groups considered
at high risk, including children of mothers who receive al-
cohol treatment services and children in state care.
Screening for FASD provides a means to facilitate re-
ferral, diagnosis and support [6]; however, several factors
complicate the identification of, and screening for, FASD
[12]. Screening for FAS has primarily utilised identifica-
tion of the three characteristic FAS facial anomalies
(short palpebral fissures, smooth philtrum and thin
upper lip) that are collectively specific to FAS [25]; al-
though routinely collected data from neonatal medical
records including growth, head circumference, maternal
alcohol use and other criteria have also been used [26].
Screening for FAS using facial photographs to detect the
characteristic facial anomalies has been found to be ef-
fective in high-risk populations in North America, with
a positive predictive value of 86% and a negative predict-
ive value of 100% [27].
Screening for FASD is more difficult because facial
dysmorphology is frequently absent, impairments of
neurological function are predominant [6], and the
neurobehavioural features are not unique to FASD [28].Inconsistency in the methods used for screening and re-
ferral internationally [29] is linked to a lack of screening
instruments for FASD that are specific and sensitive to
the fetal effects of prenatal alcohol exposure [6]. Bio-
chemical screening has the potential to facilitate early
diagnosis; however, apart from the detection of ethyl
esters in newborn meconium, screening methods are not
well established [30,31]. Heterogeneity among the
observed features of FASD due to variation in genetic
factors, patterns of alcohol exposure and other maternal
risk factors adds to the complexity of screening for
FASD [29]. Nevertheless, the use of standard screening
processes may facilitate the appropriate identification of
individuals who require specialist diagnostic assessment.
Screening programs for both FAS and FASD fre-
quently use assessment methods that are directly linked
to diagnostic criteria. Published screening assessments
have included prenatal alcohol exposure, weight, height,
head circumference, developmental delay, learning diffi-
culties, behavioural problems and the presence of char-
acteristic FAS facial anomalies [9,26,32]. However,
screening programs do not always assess the full range of
diagnostic features. For example, facial dysmorphology as-
sessment has been excluded from FASD screening cri-
teria [9,32], consistent with the recommended need for
experienced assessors, the infrequent occurrence of fa-
cial anomalies among individuals with FASD, and the
lack of norms for ethnically diverse populations [29].
There is little locally-relevant evidence on which to
base policy decisions about FASD screening in Australia.
There is no coordinated national approach to facilitate
the identification of FASD in Australia, and it is unclear
to what extent current policy and capacity for service
delivery are consistent with clinician perspectives of pri-
orities and needs. We aimed to evaluate perceptions
about screening for FASD among Australian health
professionals with experience or expertise in FASD
screening or diagnosis to guide research and policy on
FASD screening in Australia.
Methods
A modified Delphi process [33] was used to assess
Australian health professionals’ perceptions of the need for
and process of FASD screening in Australia. The modified
Delphi design generally diverges from the classical Delphi
method in the use of alternative means to derive the content
of the initial quantitative questionnaire round [33] while still
allowing the collection of rich data based on multiple ques-
tionnaire iterations [34]. Modified Delphi studies are par-
ticularly appropriate where relevant knowledge exists.
Questionnaire development
An existing systematic review on FASD screening and
diagnosis [35] was used to identify literature relevant to
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search strategy for this review was updated to include
literature published up to and including September
2010, and expanded to include additional search terms
(fetal alcohol effects, fetal alcohol disorders, partial fetal
alcohol syndrome, alcohol related birth defects, alcohol
related neurodevelopmental disorder, screen$, diagnos$).
Additional relevant databases were also searched
(CINAHL, PsychINFO and Web of Science).
Descriptions of screening programs identified in the
published literature were used to design Likert statements
to evaluate perceptions about screening coverage, screening
components, and assessment methods. Participants were
asked to rate their agreement with each statement on a
5-point Likert scale which ranged from ‘strongly agree’
to ‘strongly disagree’, and a response option of ‘no
comment’ was provided to enable participants to indi-
cate that a statement was outside their area of expert-
ise. Each question area also included open ended questions
and participants were encouraged to provide comments on
their responses and identify where the statements did not
reflect their beliefs. The questions on screening were
administered as part of a larger survey on the screening
and diagnosis of FASD in Australia. Perceptions about the
diagnosis of FASD have been reported elsewhere [36]. The
questionnaire was pilot tested with 16 health professionals
and health researchers to examine coherence, feasibility
and face validity prior to administration.
Panel recruitment
We aimed to recruit a large panel of Australian health
professionals with experience or expertise in FASD
screening or diagnosis. Panel members were identified
using three purposive sampling strategies [37]: i) medical
practitioners who reported a diagnosis of FAS to the
Australian Paediatric Surveillance Unit (APSU) in a pre-
vious study [15], ii) health professionals who were identi-
fied by study investigators as having experience or
expertise in FASD screening or diagnosis, and iii)
individuals who responded to calls to health professional
organisations for individuals who had relevant experi-
ence or expertise.
Recruitment of panel members with relevant experi-
ence or expertise underpins the validity of this study,
and processes used to enrol panel members varied by
sampling strategy based on the need to confirm relevant
expertise prior to enrolment. Information about this
study was distributed to 57 eligible medical practitioners
who had reported a diagnosis of FAS to the APSU, and
all were included in the study apart from 17 who either
actively declined to participate or who could not be
contacted (based on an invalid email address or an
automated email reply). In contrast, all other invited
health professionals were only included in the panel ifthey actively confirmed their suitability and willingness
to participate. Among these 149 invited health professionals,
90 accepted the invitation to participate. The modified
Delphi process commenced with 130 Australian panel
members: including 40 who had reported a diagnosis
of FAS to the APSU, 59 who were identified as having ex-
perience or expertise in FASD screening or diagnosis, and
31 who were recruited from professional organisations.
Questionnaire administration
The online password-protected questionnaire was administered
from a secure web server, and responses were automatically
saved to a secure MySQL database. All panel members
were invited by email to complete the first round ques-
tionnaire within 14 days, and two email reminders were
sent prior to the round deadline. Due to requests for a
longer period for response, the round 1 deadline was
extended by 8 days, and 21 days was provided for re-
sponse to the round 2 questionnaire. Where contact
details were available, panel members who had not visited
the study website were targeted for additional follow-up.
One contact attempt was made by telephone at least 5
days before the closure date of rounds 1 and 2.
Participants who did not complete round 1 were excluded
from round 2.
Round 2 questionnaire revision
Both quantitative and qualitative responses were considered
in the questionnaire revision process. Due to the length of
the round 1 questionnaire, revisions aimed to minimise the
length of the round 2 questionnaire and exclude question
areas that had achieved consensus. If at least 70% of
participants agreed or strongly agreed with a statement, it
was considered endorsed. This level of consensus was
decided a priori. If fewer than 60% of participants agreed
or strongly agreed with a statement, the statement was
rejected or modified based on qualitative findings. How-
ever, where multiple statements were related to the same
issue, consensus was sought for the question area rather
than for each statement in isolation. As such, several
statements that either achieved consensus agreement or
less than 60% agreement were included in round 2 where
clear consensus was not achieved for that question area.
New statements were also included in round 2 if qualita-
tive findings indicated that the round 1 questionnaire
failed to represent a relevant alternative perspective. The
round 2 questionnaire included feedback of representative
comments as well as group and individual per cent agree-
ment results from round 1 to enable participants to reflect
on their previous responses.
Analysis
Descriptive statistics were generated for each statement,
including response frequencies and dispersion (inter-
Table 1 Summary of participant characteristics in round 1
Characteristic n (%)
(n=95)
Sex
Male 24 (25)
Female 71 (75)
State†
Australian Capital Territory 1 (1)
New South Wales 23 (26)
Northern Territory 5 (6)
Queensland 23 (26)
South Australia 6 (7)
Tasmania 3 (3)
Victoria 4 (5)
Western Australia 24 (27)
Occupation
Paediatricians 44 (46)
Non-paediatrician medical practitioners 22 (23)
Other health professionalsΔ 29 (31)
Experience in FASD diagnosis‡
Yes 38 (41)
No 55 (59)
Experience in FASD screening, diagnosis or contributing* to
diagnosis‡
Yes 70 (75)
No 23 (25)
Completed specific training on FASD diagnosis‡
Yes 20 (22)
No 73 (79)
Work location‡
Includes rural or remote practice 41 (44)
Does not include rural or remote practice 52 (56)
†Valid n = 89.
‡Valid n = 93.
ΔOther health professionals includes nurses, allied health professionals, health
workers and health researchers.
*Contribution to diagnosis includes the conduct of relevant assessments that
inform diagnosis, but not determination of the final diagnosis.
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key statements on screening coverage and individual
characteristics, were explored using the Chi square test
or Fisher’s exact test [38]. The Wilcoxon signed rank test
was used to compare agreement between statements on
screening coverage, and between alternative screening
methods for growth. All analyses were evaluated using
two-tailed test statistics.
Qualitative data were coded and analysed independ-
ently by two investigators using an inductive content
analysis approach [39,40]. Data from each open ended
question were reviewed alongside the quantitative data,
compared and coded based on the underlying meaning
of the responses. Both analysts’ coding schemes were
reviewed for consistency to ensure credibility and trust-
worthiness of the analysis process [39]. This study was
approved by the University of Western Australia Human
Research Ethics Committee and the Western Australian
Aboriginal Health Information and Ethics Committee.
Results
Of the 130 panel members, 95 (73%) responded in round
1, and 81 of these 95 (85%) responded in round 2. Re-
sponse in round 1 was: 68% (27/40) among panel
members who reported a diagnosis of FAS to the APSU;
78% (46/59) among panel members recruited by the
study investigators; and 71% (22/31) among panel
members recruited through professional organisations.
Round 1 participants were most commonly paediatricians
(46%), and approximately three quarters reported experi-
ence in FASD screening or diagnosis (Table 1).
Screening coverage
Due to a lack of consensus on the use of targeted
screening at birth following round 1, all four statements
evaluating screening coverage were re-administered in
round 2 (Table 2, statements 1-4). After round 2 there
was no strong evidence of a difference in agreement that
screening for FASD at birth should be targeted (76%) or
universal (55%; Wilcoxon Z=-1.7, p=0.09). Participants
most commonly agreed that screening for FASD in
childhood should be targeted (84%), and were more
likely to agree that it should be targeted than universal
(40%; Wilcoxon Z=-4.1, p<0.001). They were also more
likely to agree with the use of targeted screening in
childhood compared with targeted screening at birth
(Wilcoxon Z=-2.2, p=0.03). We found no evidence of
differences in agreement about screening coverage at
birth or in childhood according to experience in
screening or diagnosis (all p>0.7).
There was clear consensus agreement on all indications
for targeted screening evaluated in round 1 (Table 2,
statements 5-22). Over 95% of participants agreed with
screening for FASD where there is parental concern thattheir child may have a FASD; evidence of characteristic
FAS facial anomalies; an alcohol-related illness or depend-
ency in the birth mother; and a sibling with FASD.
In round 1, 61 participants (64%) provided comments
about their preferences for screening coverage. Comments
most frequently indicated support for universal screening
as an ideal and ethical approach that decreases the risk of
missed cases, helps overcome the limitations of a poten-
tially unreliable maternal alcohol history, and enables early
diagnosis and intervention. However, targeted screening
Table 2 Agreement with statements on screening coverage and indications in rounds 1 and 2
Statement R1 N R1 % Agree† (IQD) R2 % Agree† (IQD)
Screening coverage
1. Screening for FASD at birth should be universal 87 58 (3) 55 (3)
2. Screening for FASD at birth should be targeted 88 68 (2) 76 (1)
3. Screening for FASD in childhood should be universal 86 49 (3) 40 (2)
4. Screening for FASD in childhood should be targeted 86 78 (1) 84 (1)
Indications for targeted screening - presentations
5. an alcohol-related event, illness or dependency in the birth mother 91 96 (1) -
6. a parent/foster parent who is concerned that their child might have a FASD 91 99 (1) -
7. prenatal alcohol exposure 90 92 (1) -
8. developmental delay 88 91 (1) -
9. growth retardation or failure to thrive 87 91 (1) -
10. structural central nervous system abnormalities 82 87 (1) -
11. neurological signs 84 82 (1) -
12. functional central nervous system abnormalities 84 88 (1) -
13. characteristic FAS facial anomalies 89 97 (1) -
14. birth defects 85 93 (1) -
15. reported or observed problems with behaviour 88 86 (1) -
Indications for targeted screening – high risk groups
16. children of mothers attending alcohol treatment services 91 93 (1) -
17. siblings of identified cases of FASD 90 96 (1) -
18. children who are diagnosed with ADHD 82 74 (2) -
19. children entering a child development service 89 87 (1) -
20. children entering child protection 86 85 (1) -
21. children entering foster care or adoptive placements (incl. kinship care) 86 87 (1) -
22. children entering a juvenile justice setting 84 82 (1) -
R1-Round 1; R2-Round 2; IQD-inter-quartile deviation.
†Includes responses ‘agree’ and ‘strongly agree.’
Results for statements that reached 70% agreement (consensus) are presented in bold.
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feasible and effective approach. Participants commonly iden-
tified practical constraints associated with screening and
diagnosis, including the need for increased service capacity
and provider training, the need for adequate early interven-
tion services, and the evolving and variable nature of FASD
presentations. Respondents also expressed concerns about
the absence of well-established or accurate screening tests
and the sensitivity, specificity and cost-effectiveness of
screening. They also indicated support for the universal
collection of a maternal history of alcohol use during
the prenatal period and at birth to enable preventive
interventions and targeted follow-up. Participants less
commonly described adverse psychosocial consequences
of screening or of assigning an aetiological diagnostic
label such as maternal blame or stigma; and a lack of
support for screening programs which focus on a sin-
gle condition.Components of screening
Consensus was achieved for all components of screening
assessed apart from the testing of fatty acid esters (Table 3,
statements 1-8 and 12-21). Some participants commented
in round 1 that the agreed components of screening for
FASD were already routinely assessed at birth or dur-
ing the assessment of neurodevelopmental problems
presenting in childhood; that the primary need is for
health professionals to assess prenatal alcohol expos-
ure and consider it as a potential cause of identified
abnormalities; and that a screening checklist and criteria
for referral are required. Additional statements were
included in the round 2 questionnaire to evaluate
participants’ perceptions of these issues (Table 3,
statements 9-11 and 22-24). Following round 2 there
was no consensus agreement that information required for
screening is currently routinely collected. However, there
was consensus agreement that screening primarily requires
Table 3 Agreement with statements on the components of screening at birth and in childhood in rounds 1 and 2
Statement R1 N R1 % Agree† (IQD) R2 % Agree† (IQD)
Screening at birth
1. prenatal alcohol exposure 92 98 (1) -
2. birth weight, length and head circumference 90 100 (1) -
3. fatty acid esters (FAEE) in meconium collected within 72 hours of birth 37 46 (3) -
4. characteristic FAS facial anomalies 89 98 (1) -
5. birth defects 89 98 (1) -
6. evidence of withdrawal from alcohol or other drugs 90 99 (1) -
7. family history of FASD or developmental delay 79 - 95 (1)
8. evidence of CNS dysfunction including irritability, feeding difficulties or other
neurological signs
77 91 (1)
9. most of the information required for FASD screening at birth is routinely
collected at birth
72 - 56 (2)
10. screening for FASD at birth primarily requires health professionals to assess
prenatal alcohol exposure and
consider it as a potential cause of other relevant abnormalities identified
79 - 86 (1)
11. a checklist is needed to support the implementation of screening for FASD
at birth that identifies the
components to be assessed and criteria for conducting a full diagnostic evaluation
79 - 84 (1)
Screening in childhood
12. prenatal alcohol exposure 90 97 (1) -
13. growth (height and weight) 89 98 (1) -
14. head circumference 86 99 (1) -
15. developmental delay 89 99 (1) -
16. neurological signs 87 93 (1) -
17. functional CNS abnormalities (e.g. cognition, behaviour disorders) 88 99 (1) -
18.hearing and vision 85 93 (1) -
19. characteristic FAS facial anomalies 89 98 (1) -
20. birth defects 89 97 (1) -
21. family history of FASD, developmental delay, abuse or neglect 78 - 97 (1)
22. most of the information required for FASD screening in childhood is
routinely assessed as part of a
general clinical assessment of children with neurodevelopmental or other
related presentations
71 - 59 (2)
23. screening for FASD in childhood primarily requires health professionals to
assess prenatal alcohol exposure
and consider it as a potential cause of other relevant abnormalities identified
(e.g. abnormalities of
development, learning, behaviour)
77 - 88 (1)
24. a checklist is needed to support the implementation of screening for
FASD in childhood that identifies the
components to be assessed and criteria for conducting a full diagnostic
evaluation
78 - 90 (1)
R1-Round 1; R2-Round 2; IQD-inter-quartile deviation; CNS-central nervous system.
†Includes responses ‘agree’ and ‘strongly agree.’
Results for statements that reached 70% agreement (consensus) are presented in bold.
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and consider it as a potential cause of other relevant ab-
normalities identified at birth (86%) and in childhood
(88%); and that a screening checklist is required to iden-
tify criteria for referral at birth (84%) and in childhood
(90%).Participant comments linked improved awareness of
and ability to screen for FASD with improved case iden-
tification. Screening for prenatal alcohol exposure, al-
though potentially unreliable, was considered by some
participants to be the most important element of
screening for FASD due to the difficulty of screening for
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nervous system (CNS) dysfunction is often not apparent
in very young children. Other participants referred to diffi-
culties in screening associated with nondisclosure of alco-
hol use during pregnancy, or where no maternal
history is available. Several participants also identified
the limited usefulness of screening for facial anomalies
when screening for FASD.
Assessment methods
Almost all statements on screening assessment methods
achieved consensus in round 1 (Table 4). There was a
high level of agreement that the assessment of prenatal
alcohol exposure should identify and record the number
of standard drinks consumed on a typical drinking occa-
sion, the frequency of drinking, the frequency of exces-
sive drinking and the timing of alcohol intake during
pregnancy (Table 4, statements 1-5). Most participants
(71%) believed that prenatal alcohol exposure should be
assessed using a formal tool (Table 4, statements 6-7).
The most commonly recommended formal assessment
tool was the AUDIT-C (21%) [41], followed by Lifescripts
(17%) [42] which incorporates the AUDIT-C, T-ACE
(14%) and TWEAK (13%) [43]. Most participants reported
that they were not familiar with the Lifescripts (63%),
TWEAK (62%), T-ACE (62%) and AUDIT-C (59%) tools,
and no alternative formal assessment tools were proposed.
Following round 2, the role of informal inquiry in prenatal
alcohol exposure assessment was clarified, with consensus
agreement for the combination of informal and formal
methods of inquiry. After receiving further information
about the AUDIT-C in round 2, 89% of participants
considered that it provided a useful screening tool for pre-
natal alcohol exposure (Table 4, statements 8-10).
Participants most frequently supported the compari-
son of height and weight with population standards to
assess growth deficit (Table 4, statements 11-14), and
there was a high level of consensus on the specific facial
anomalies that should be assessed during screening
(Table 4, statement 15). Participant comments in round
1 indicated a lack of distinction between screening and
diagnostic assessments, the need for training to use fa-
cial anomaly assessment tools reliably, the lack of suit-
able Australian reference data for comparison, and the
need for screening methods to be efficient. Following
round 2 there was consensus agreement that formal as-
sessment of facial anomalies could be used, but was not
required, to assess facial anomalies at the screening stage
(Table 4, statements 17-22).
There was agreement on the assessment of a broad
range of CNS abnormalities in screening, and limited
support for the use of brain imaging (Table 5, statements
1-14). Participant comments in round 1 highlighted the
need to distinguish between screening and diagnosticassessments, and the need for a pragmatic approach to
assessment considering cost and resources, including the
possibility of qualitative assessment of core areas at the
screening stage. Round 2 results indicated agreement
that clinical identification or third party report were ac-
ceptable indicators of CNS abnormality at the screening
stage (Table 5, statements 18-21).
Response completeness
Over half of the 95 participants (57%) completed 10 or
fewer of the round 1 Likert statements on screening.
Non-complete responses most commonly included a re-
sponse of ‘no comment’, indicating that the statements
were outside participant’s areas of expertise. Completion
of 10 or fewer statements was more frequent among
participants who reported no experience in diagnosis or
screening (87%) and health professionals other than
paediatricians (73%) than among participants who
reported experience in diagnosis or screening (49%,
χ2=11.7, p=0.001) and paediatricians (39%, χ2=11.3,
p=0.001) respectively.
Assessment of the association between response com-
pleteness and perceptions found clear evidence of an as-
sociation with response completeness for only one of the
statements about screening coverage, components, and
assessment methods. Participants who completed 10 or
fewer statements were less likely to agree with the use of
clinician preference and experience in the choice of
neuro-behavioural assessment methods (42%) compared
with participants who completed more than 10 statements
(73%, χ2=7.2, p=0.007: Table 5, item 16).
Discussion
This is the first systematic evaluation of health professionals’
perceptions of the need for and design of screening for
FASD in Australia. We found consensus support for
targeted screening, and more frequent agreement with
screening in childhood than at birth. Although about half
the participants supported the need for universal screening
for FASD as an ideal and ethically responsible approach to
minimise missed cases, consensus agreement was only
achieved for targeted screening of individuals with relevant
clinical presentations and groups at high risk of FASD. Par-
ent or caregiver concern that their child may have a FASD
and clinical presentations associated with the likelihood of
prenatal alcohol exposure were most strongly endorsed as
indications for targeted screening.
Targeted screening was considered more cost effective
and feasible than universal screening, with support for
targeted screening linked to constraints on service
provision, including the need for provider training and
increased demand for diagnostic and intervention services.
Participants were also concerned about the limitations of
existing screening methods and the need for programs
Table 4 Agreement with statements on screening assessment methods for prenatal alcohol exposure, growth deficit
and characteristic fetal alcohol syndrome facial anomalies in rounds 1 and 2
Statement R1
N
R1 % Agree†
(IQD)
R2 % Agree†
(IQD)
Prenatal alcohol exposure
Assessment of prenatal alcohol exposure should identify and record the:
1. . . . number of standard drinks consumed during a typical drinking occasion 85 98 (1) -
2. . . . frequency of drinking occasions 86 98 (1) -
3. . . . frequency of excessive (binge) drinking (5+ standard drinks per occasion) 86 95 (1) -
4. . . . timing of alcohol intake during pregnancy 86 97 (1) -
5. Alcohol exposure should be assessed alongside other lifestyle factors (e.g. diet) 85 92 (1) -
6. Prenatal alcohol exposure can be effectively assessed using an informal approach (e.g. inquiring during a
consultation)
82 52 (2) 41 (2)
7. Prenatal alcohol exposure should be assessed using a formal tool 69 71 (2) -
8. The use of formal tools for the assessment of prenatal alcohol exposure should be combined with a clinical
interview to obtain more detailed information about alcohol consumption patterns, potential indicators of
addiction and other relevant contextual information
80 - 88 (1)
9. Information on alcohol use from family members, other health professionals or community members (if
appropriate) should be sought if indicated
78 - 77 (0)
10. The AUDIT-C would be a useful tool for the formal assessment of prenatal alcohol exposure 74 - 89 (0)
Growth deficit
11. Growth should be assessed by comparing height and weight with population standards 70 93 (1)1 -
12. Growth should be assessed by comparing weight to height ratio with population standards 66 68 (2) 1 -
13. Growth should be assessed by comparing weights over time (to identify decelerating weight over time) 68 90 (1) 1 -
14. Assessment of growth deficit should consider other factors that may affect growth (e.g. gestational age
parental size, gestational diabetes, nutritional status, illness)
78 100 (1) -
Characteristic fetal alcohol syndrome (FAS) facial anomalies
15. The presence of the following characteristic FAS facial anomalies should be assessed: smooth philtrum,
thin upper lip, and small palpebral fissures
81 100 (1) -
16. Assessment of characteristic FAS facial anomalies should use appropriate anthropometric population
standards for race and age where available
77 95 (1) -
At the screening stage, characteristic FAS facial anomalies can be effectively assessed using:
17. . . . clinical observation(R1) /Facial anomalies can be assessed using clinical observation for evidence of the
characteristic FAS facial anomalies, with formal physical measurement of these features not essential at the
screening stage (R2)
69 73 (1) 77 (0)
18. . . . physical measurement of palpebral fissures 50 76 (0) -
19. . . . the University of Washington Lip-Philtrum Guide 49 86 (1) -
20. . . . the facial photographic screening tool 45 76 (1.5) -
21. Palpebral fissure length must be assessed using formal physical measurement and comparison with
population references at the screening stage
62 - 39 (2)
22. Thin upper lip and smooth philtrum must be assessed using formal tools such as the University of
Washington Lip-Philtrum Guide at the screening stage
61 - 46 (2)
R1-Round 1; R2-Round 2; IQD-inter-quartile deviation.
†Includes responses ‘agree’ and ‘strongly agree’.
Results for statements that reached 70% agreement (consensus) are presented in bold.
1Friedman test indicated a significant difference in agreement with the 3 statements that described different methods to assess growth (statements 11-13:
Friedman chi-square=19.3, p<0.001). Post-hoc testing found a significant difference between ratings for statements 11 and 12 (Wilcoxon Z=-3.5, p<0.001) and 12
and 13 (Wilcoxon Z=-3.1, p=0.002).
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effectiveness. These findings reflect previously identi-
fied difficulties in screening for FASD [20,29,30], and
deficits in diagnostic and management capacity to sup-
port screening [9,14,15,29,44,45].We found consensus agreement on the need for a
checklist and criteria for referral to support the imple-
mentation of screening for FASD. We also found con-
sensus agreement that screening primarily requires
health professionals to assess prenatal alcohol exposure
Table 5 Agreement with statements on screening assessment methods for central nervous system abnormalities in
rounds 1 and 2
Statement R1
N
R1 % Agree†
(IQD)
R2 % Agree†
(IQD)
Central nervous system (CNS) abnormalities
Assessment of CNS abnormalities in FASD screening may include:
1. . . . developmental milestones 80 96 (1) -
2. . . . motor and sensory function 77 88 (1) -
3. . . . cognition (IQ) 79 92 (1) -
4. . . . memory 78 89 (1) -
5. . . . academic achievement 79 91 (1) -
6. . . . executive functioning and abstract reasoning 79 89 (1) -
7. . . . adaptive behaviour 75 92 (1) -
8. . . . attention and hyperactivity 80 95 (1) -
9. . . . communication (receptive and expressive language) 78 94 (1) -
10. . . . social skills and social communication 80 93 (1) -
11. . . . hard and soft neurologic signs (including sensory-motor signs) 74 87 (1) -
12. . . . seizures that are not due to a postnatal insult or other postnatal process 74 78 (1) -
13. . . . head circumference 78 96 (1) -
14. . . . brain imaging 67 57 (1) -
The choice of tests for neuro-behavioural assessments should be guided by:
15. . . . the availability of valid and reliable instruments 76 90 (1) -
16. . . . clinician preference and experience 74 60 (2) ‡ -
17. . . . test appropriateness for patient age and cultural background 78 97 (1) -
18. At the screening stage it is not necessary to formally assess and measure suspected CNS anomalies 68 - 72 (1)
At the screening stage the following are acceptable indicators of possible CNS abnormalities (neurological,
functional or structural):
19. . . . clinical identification 66 - 97 (0)
20. . . . parent or other credible third party report 66 - 91 (0)
21. . . . results of previous relevant formal assessments (e.g. psychological report) 65 - 100 (1)
Birth defects
22. FASD screening should assess and record the presence of birth defects as part of the clinical
examination
81 99 (1) -
R1-Round 1; R2-Round 2; IQD-inter-quartile deviation.
†Includes responses ‘agree’ and ‘strongly agree’.
‡Statement excluded from round 2 as proportion agreement was 59.5%.
Results for statements that reached 70% agreement (consensus) are presented in bold.
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These findings are consistent with the need for greater
awareness of FASD and improved capacity for screening
among Australian health professionals [46,47], and high-
light support for targeted screening as a strategy which
can be integrated into usual clinical practice and passive
case finding. Over half of participants agreed that most
of the information required for FASD screening is
assessed at birth or during relevant clinical presentations
in childhood, which indicates some capacity for FASD
screening in Australia. However, perceptions of participants
in this study could differ systematically from healthprofessionals who do not have experience or expertise in
FASD screening or diagnosis.
Participants indicated that standard, explicit and effi-
cient screening criteria are needed to determine when
referral for a diagnostic evaluation is required. Few for-
mal, validated instruments for FASD screening exist, and
no single instrument is suitable for all ages and settings
[29]. The absence of a single common distinguishing
feature of FASD that can be used to indicate the need
for a diagnostic evaluation has required programs to use
aetiological risk factors and diagnostic features to de-
termine whether a diagnostic evaluation is required.
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unreliable, time consuming and rudimentary [48],
most participants supported the use of screening
indicators linked to aetiological and diagnostic factors,
and emphasised the need to identify efficient and ef-
fective screening criteria.
Inaccurate FASD screening and case ascertainment
have been linked to deficits in practitioner training and
the use of inconsistent case definitions [8,26]. Formal as-
sessment of facial dysmorphology and functional CNS
performance at the screening stage was not considered
necessary, reliable or appropriate in all settings. The
need for valid population reference data for comparison
was also identified. Although more than half of participants
were not familiar with the formal assessment instruments
for alcohol exposure presented, we found consensus agree-
ment on the need for formal assessment methods, and on
the usefulness of the AUDIT-C assessment instrument [41]
following description of this instrument in round 2.
The facial photographic screening tool was considered
to provide a feasible alternative to the measurement of
facial anomalies by inexperienced assessors, although
some participants indicated concerns about the use of
facial dysmorphology assessment in FASD screening.
While facial anomalies have been used to screen for FAS
[26,27,29] facial anomalies are not commonly assessed in
FASD screening [9,32]. The assessment of facial anomal-
ies has been considered inappropriate in general popula-
tion screening for FASD due to multiple factors, including
its low predictive value for FASD [29]. However, diagnos-
tic guidelines and criteria for referral recognise the signifi-
cance of the characteristic FAS facial anomalies as an
indicator of the need for diagnostic evaluation, particularly
in the absence of confirmed prenatal alcohol exposure
[6,9,12].
Criteria have been established to identify when popula-
tion screening is appropriate and ethically justified, and to
ensure that screening does more good than harm [49]. The
variable application of these criteria in practice has been
attributed to their inherent subjectivity and a lack of evi-
dence to comprehensively evaluate screening interventions
[50]. Criteria for the evaluation of population-based
screening interventions include whether the potential im-
pact of the condition is sufficient to justify screening;
whether there is a benefit from early diagnosis and treat-
ment; whether there is a cost-effective and acceptable
screening test; and whether appropriate diagnostic services
and treatment are available [49-51]. Our finding of a lack
of consensus on the need for universal screening of appar-
ently healthy individuals is consistent with the failure of
FASD screening to meet some of these requirements.
Targeted screening for high risk presentations and
groups was supported as a strategy to improve the identifi-
cation of FASD in Australia, consistent with developmentsin health policy [23]. Participant comments emphasised
the importance of ensuring the effectiveness of screening
interventions prior to their use to ensure that the interven-
tion benefits both individuals screened and the community.
There is little reliable information on the epidemiology of
FASD in Australia, and it is not clear what proportion of
individuals with FASD would be identified by targeted
screening of high-risk groups. Our findings highlight the
complex issues that must be addressed when pursuing the
deceptively simple objective of early diagnosis [49], and the
real need for systematic evaluation of the risks and benefits
of proposed screening interventions [50].
The Delphi method provides a strong basis for the
construct validity of the study findings, with participants
able to validate their initial responses and identify areas
of uncertainty [34]. This study was primarily based on
an exploration of established screening methods, and
our use of non-representative sampling and a modified
Delphi process may have limited our ability to evaluate
all potentially relevant information on the design of
FASD screening programs in Australia. Nevertheless,
participants provided diverse perspectives on the use of
screening for FASD, including the identification of risks
associated with screening, and the importance of both
individual case finding and a population based approach.
Further research is needed to evaluate potential strat-
egies to facilitate improved identification of FASD, and
to evaluate their performance and acceptability in the
Australian context.
We aimed to recruit health professionals who had spe-
cific experience or expertise in FASD screening or diag-
nosis to identify consensus perceptions on the approach
to FASD screening in Australia. Paediatricians were most
highly represented within the study sample, reflecting
the profession’s key role in diagnosis in Australia. The
round 1 response in this study exceeded the 70%
recommended level [52] and was similar to that
observed in other Delphi studies involving clinician
panels [53,54]. Attrition was greatest between the time
of agreement to participate in the study and returning
the round 1 questionnaire, and similar to that reported
by others [53]. Delay between recruitment of the panel
and distribution of the questionnaire, as well as the re-
cruitment of a large panel [55] may have reduced re-
sponse in this study. Although we found response
completeness was associated with participant occupa-
tion and experience, there was little evidence of
differences in perceptions about screening according
to response completeness.
Evaluation of pilot screening interventions are required
to address the lack of evidence to support the effectiveness
of screening for FASD in Australia and identify the impact
of screening parameters on program outcomes and effect-
iveness. This approach to development would enable
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ability to engage with high risk groups. The development
of effective screening interventions can improve our
understanding of the epidemiology of FASD and its preva-
lence in high risk groups; contribute to the identification
of appropriate strategies for FASD management and pre-
vention; and provide an empirical evidence base for FASD
policy in Australia.
It is clear from our findings that additional strategies are
also required to improve passive case-finding, referral and
diagnosis in Australia. Signs of FASD are frequently non-
specific, and barriers to seeking or accessing appropriate
diagnostic and intervention services are likely to be im-
portant obstacles to passive case finding. Strategies that
can be used to improve passive case finding capacity and
the identification of FASD in Australia include the devel-
opment of resources and programs to improve awareness
of the disorders and their prevention among health
professionals, other relevant professionals and the wider
community; the development of standard criteria to guide
health professionals on appropriate referral of individuals
who require specialist assessment, as implemented in
North America [6,12]; and improved diagnostic capacity
and access to specialist services.
Conclusion
Our findings provide an agreed basis for the develop-
ment and evaluation of targeted screening for FASD in
high risk groups, standard criteria for referral, and other
strategies to improve passive case identification, includ-
ing improved awareness of the disorders among health
professionals. Health professionals require well-defined,
effective and ethically justified methods to identify and
refer individuals who require specialist diagnostic assess-
ment, and appropriate training to deliver these services.
Established capacity for diagnosis and management is
also essential, and the development of effective targeted
screening interventions can contribute to the identifica-
tion of appropriate strategies for the design and resour-
cing of FASD diagnosis, management and prevention
services in Australia.
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